You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Litigation Details for Pfizer Inc. v. Ajanta Pharma Ltd. (D. Del. 2019)

✉ Email this page to a colleague

« Back to Dashboard

Pfizer Inc. v. Ajanta Pharma Ltd. (D. Del. 2019)

Docket	⤷ Try a Trial	Date Filed	2019-03-15
Court	District Court, D. Delaware	Date Terminated	2020-06-05
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	PBG PUERTO RICO LLC
Patents	6,956,041; 6,965,027; 7,091,208; 7,265,221; 7,301,023; 7,842,699; RE41,783
Attorneys	Kenneth Laurence Dorsney
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Small Molecule Drugs cited in Pfizer Inc. v. Ajanta Pharma Ltd.

The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .

Biologic Drugs cited in Pfizer Inc. v. Ajanta Pharma Ltd.

The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .

Details for Pfizer Inc. v. Ajanta Pharma Ltd. (D. Del. 2019)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try a Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2019-03-15	1	Complaint	additional patents for Xeljanz 5 mg Tablets that are not at issue: U.S. Patent Nos. 6,956,041 (expiring…United States Patent No. 6,965,027 (the “’027 patent”) and United States Reissue Patent No. RE41,783 …expiration dates for the ’027 patent as March 25, 2023, and the RE’783 patent as December 8, 2025. …. The ’027 Patent 20. On November 15, 2005, the USPTO issued the ’027 patent, titled “Crystalline….” The ’027 patent is duly and legally assigned to Pfizer Inc. A copy of the ’027 patent is attached	External link to document
2019-08-29	16	Complaint - Amended	additional patents for Xeljanz Tablets that are not at issue: U.S. Patent Nos. 6,956,041 (expiring December…United States Patent No. 6,965,027 (the “’027 patent”) and United States Reissue Patent No. RE41,783 …expiration dates for the ’027 patent as March 25, 2023, and the RE’783 patent as December 8, 2025. …). The ’027 Patent 20. On November 15, 2005, the USPTO issued the ’027 patent, titled “Crystalline….” The ’027 patent is duly and legally assigned to Pfizer Inc. A copy of the ’027 patent is attached	External link to document
2019-10-04	30	Notice of Service	Ajanta Pharma USA Inc. and United States Patent Nos. 6,965,027 and RE 41,783 filed by C.P. Pharmaceuticals… 2019 5 June 2020 1:19-cv-00517 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-03-15	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE41,783 E ;6,965,027 B2. (rwc) (Entered… 2019 5 June 2020 1:19-cv-00517 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.